NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay

Lisa A Ridnour1, Robert Y S Cheng2, Jonathan M Weiss3

  • 1Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. ridnourl@mail.nih.gov.

Cancer Research
|May 21, 2015
PubMed

Insights

Targeting nitric oxide synthases (NOS) after radiation therapy enhances tumor growth delay by promoting a beneficial immune response. This strategy involves inhibiting NOS to shift the immune environment towards anti-tumor activity.

Area of Science:

  • Oncology
  • Immunology
  • Radiotherapy

Background:

  • Nitric oxide synthases (NOS) play a role in tumor growth, angiogenesis, and immune modulation.
  • Ionizing radiation (IR) also affects the immune system and wound healing processes.
  • Targeting NOS post-IR may enhance radiation therapy efficacy.

Purpose of the Study:

  • To investigate the effect of NOS inhibition on radiation therapy outcomes.
  • To elucidate the role of T cells and cytokine modulation in radiation response.
  • To determine if NOS inhibition can improve anti-tumor immunity after irradiation.

Main Methods:

  • Utilized syngeneic (C3H) and immunosuppressed (Nu/Nu) mouse models of squamous cell carcinoma.
  • Administered N(G)-nitro-l-arginine methyl ester (L-NAME), a NOS inhibitor, post-IR.
  • Measured tumor growth delay, IL10 cytokine levels, and T cell populations (Th1/Th2, CD8+).
  • Investigated mechanisms in cultured Jurkat T cells and ANA-1 macrophages using NOS and guanylyl cyclase inhibitors.

Main Results:

  • Post-IR L-NAME treatment significantly enhanced radiation-induced tumor growth delay in syngeneic but not immunosuppressed mice.
  • IR increased immunosuppressive IL10, which was reduced by L-NAME.
  • L-NAME treatment led to elevated cytotoxic Th1 cytokines (IL2, IL12p40, IFNγ) and CD8+ T cells in tumors.
  • NOS inhibition suppressed IR-induced IL10 in T cells and macrophages, suggesting a role for eNOS.

Conclusions:

  • Post-IR NOS inhibition improves radiation tumor response by enhancing T cell-mediated immunity.
  • The mechanism involves suppressing immunosuppressive IL10 and promoting Th1 immune polarization.
  • Targeting NOS represents a potential strategy to augment the efficacy of radiation therapy.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
34
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K